Preclinical data shows use of megalin receptors for intracellular delivery of a ligand-siRNA conjugate to silence production of target mRNA in the kidney Megalin-binding genetic medicines are ...
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues ...
A startup focused on developing oligonucleotide-based silent RNA treatments for systemic and renal diseases is emerging from stealth mode, launching with $100 million in combined seed and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company’s launch and $100 million in initial ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie is entering a collaboration and license option deal ...
The MarketWatch News Department was not involved in the creation of this content. TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech ...
Variations in conjugation chemistry conditions can lead to differences in stoichiometries and, ultimately, impact drug safety and efficacy. Therefore, there is an urgent need to measure multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results